| Veröffentlichte Version Download ( PDF | 905kB) | Lizenz: Creative Commons Namensnennung 4.0 International |
Fecal Arachidonic Acid: A Potential Biomarker for Inflammatory Bowel Disease Severity
Huss, Muriel, Elger, Tanja, Kunst, Claudia, Loibl, Johanna, Krautbauer, Sabrina, Liebisch, Gerhard
, Kandulski, Arne
, Müller, Martina, Tews, Hauke Christian und Buechler, Christa
(2025)
Fecal Arachidonic Acid: A Potential Biomarker for Inflammatory Bowel Disease Severity.
International Journal of Molecular Sciences 26 (9), S. 4034.
Veröffentlichungsdatum dieses Volltextes: 18 Jun 2025 09:21
Artikel
DOI zum Zitieren dieses Dokuments: 10.5283/epub.76892
Zusammenfassung
Arachidonic acid levels are elevated in the colonic mucosa of patients with inflammatory bowel disease (IBD). Fecal metabolites are emerging as valuable diagnostic tools for IBD. This study aimed to investigate associations between 31 fecal fatty acids, including arachidonic acid, to identify potential correlations with disease severity. Among the 31 fatty acids analyzed in feces, ...
Arachidonic acid levels are elevated in the colonic mucosa of patients with inflammatory bowel disease (IBD). Fecal metabolites are emerging as valuable diagnostic tools for IBD. This study aimed to investigate associations between 31 fecal fatty acids, including arachidonic acid, to identify potential correlations with disease severity. Among the 31 fatty acids analyzed in feces, dihomo-γ-linolenic acid, arachidonic acid, and adrenic acid were significantly increased in patients with IBD compared to controls. In contrast, levels of linoleic acid and γ-linolenic acid, the precursors of arachidonic acid, were similar between both groups. No significant differences in fatty acid levels were observed between patients with Crohn’s disease and ulcerative colitis. Arachidonic acid and adrenic acid levels positively correlated with fecal calprotectin, a clinically established marker of IBD severity, but showed no association with stool consistency or the Gastrointestinal Symptom Rating Scale. This suggests that these fatty acids are linked to disease severity rather than disease-related symptoms. Current IBD-specific medications had no significant impact on the fecal levels of any of the 31 fatty acids. In summary, this study demonstrates elevated fecal levels of dihomo-γ-linolenic acid, arachidonic acid, and adrenic acid in IBD patients. Normal levels of precursor fatty acids suggest that impaired downstream metabolism may contribute to the accumulation of these n-6 polyunsaturated fatty acids.
Alternative Links zum Volltext
Beteiligte Einrichtungen
Details
| Dokumentenart | Artikel | ||||
| Titel eines Journals oder einer Zeitschrift | International Journal of Molecular Sciences | ||||
| Verlag: | MDPI | ||||
|---|---|---|---|---|---|
| Band: | 26 | ||||
| Nummer des Zeitschriftenheftes oder des Kapitels: | 9 | ||||
| Seitenbereich: | S. 4034 | ||||
| Datum | 24 April 2025 | ||||
| Institutionen | Medizin > Lehrstuhl für Innere Medizin I | ||||
| Identifikationsnummer |
| ||||
| Stichwörter / Keywords | fatty acids; feces; calprotectin; stool consistency; inflammatory bowel disease; biomarker | ||||
| Dewey-Dezimal-Klassifikation | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||
| Status | Veröffentlicht | ||||
| Begutachtet | Ja, diese Version wurde begutachtet | ||||
| An der Universität Regensburg entstanden | Ja | ||||
| URN der UB Regensburg | urn:nbn:de:bvb:355-epub-768927 | ||||
| Dokumenten-ID | 76892 |
Downloadstatistik
Downloadstatistik